|
The instability of reagents at non-refrigerated temperatures presents a significant challenge to diagnostic companies. A short shelf life of essential reagents and the high cost of refrigerated transportation can limit the market penetration of a promising diagnostic product, particularly when profit margins are small. Arecor is currently working with a number of companies involved in the development of diagnostics for both in vitro and in vivo use. One such partnered project is the development of an indwelling sensor utilizing an enzyme required to remain active after gamma radiation and when used at a temperature close to 37°C. Arecor is achieving this through the application of Arestat-R™ and Arestat-T™ in combination.
Arecor has demonstrated that aqueous solutions of essential enzyme commonly used in diagnostic assays, such as Horadish Peroxidase and Catalase, can be maintained in a stable, functionally active state at 37°C for prolonged periods. |
|
ArestatTM comprises two fundamentally different aspects of our platform stabilization technology. Both utilize excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability
Both platform technologies are available for licensing for applications involving therapeutic proteins, vaccines, medical devices and diagnostics
|
